Filing Details

Accession Number:
0001104659-19-015281
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-03-15 16:01:38
Reporting Period:
2019-03-13
Accepted Time:
2019-03-15 16:01:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1649904 Rhythm Pharmaceuticals Inc. RYTM () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1615856 Michael Keith Gottesdiener 500 Boylston Street, 11Th Floor
Boston MA 02116
Ceo & President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-03-13 7,782 $30.06 518,138 No 4 S Direct
Common Stock Disposition 2019-03-14 1,506 $30.05 516,632 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. On March 13, 2019, Mr. Gottesdiener sold 7,782 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.20, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
  3. Includes 303 shares acquired under the issuer's 2017 Employee Stock Purchase Plan on February 28, 2019.
  4. On March 14, 2019, Mr. Gottesdiener sold 1,506 shares pursuant to a plan of disposition adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  5. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.50, inclusive; the price reported above reflects the weighted average sale price. Mr. Gottesdiener hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.